Loading viewer...
earnings
Format: PDF earnings
Krystal Biotech reported strong 2023 results following FDA approval of VYJUVEK, its first corrective therapy for dystrophic epidermolysis bullosa (DEB), with $50.7M in net product revenue in just two quarters. The company achieved significant pipeline expansion with 5 active clinical trials planned for 2024 and maintained a robust balance sheet of $594.1M in cash and investments.
earnings
37 Pages
BP
Regal Rexnord Q2 2023 Earnings Presentation
earningsearnings
31 Pages
Regal Rexnord Corporation
Navios Maritime Q2 2016 Financial Results Conference Call
earningsearnings
15 Pages
Navios Maritime Acquisition Corporation